FRONTIER CAPITAL MANAGEMENT CO LLC

Position in KYMR — Kymera Therapeutics, Inc.

CIK 351173 Boston, MA

Position in KYMR

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$84,955,104

+$21,667,365 QoQ

Shares Held

740,866

-2.5% QoQ

Ownership

0.891%

of shares outstanding

% of Portfolio

0.79%

of 13F equity value

Holder Rank

#24

of 273 holders

Holding Since

Sep 2024

8 quarters on record

Voting authority Sole 35% Shared 0% None 65%

Healthcare · as of Jun 30, 2026

FRONTIER CAPITAL MANAGEMENT CO LLC holds $975,847,387 across 22 Biotechnology names. KYMR ranks #3 (8.7% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	BBIO	BridgeBio Pharma, Inc.	1,373,057	$102,265,285
2	RARE	Ultragenyx Pharmaceutical Inc.	2,847,936	$95,092,583
3	KYMR	Kymera Therapeutics, Inc. This page	740,866	$84,955,104
4	INSM	INSMED Inc	795,242	$84,788,702
5	PVLA	Palvella Therapeutics, Inc.	478,833	$73,175,259
6	JAZZ	Jazz Pharmaceuticals plc	277,279	$66,815,920
7	AXSM	Axsome Therapeutics, Inc.	254,280	$62,240,115
8	TRVI	Trevi Therapeutics, Inc.	3,070,740	$57,269,301

8 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$84,955,104	740,866	-2.5%	Shares	Sole	2026-08-14
2026-03-31	$63,287,739	759,848	+19.5%	Shares	Sole	2026-05-15
2025-12-31	$49,483,814	635,957	+22.8%	Shares	Sole	2026-02-17
2025-09-30	$29,322,026	518,057	+5.3%	Shares	Sole	2025-11-14
2025-06-30	$21,462,588	491,810	+272.7%	Shares	Sole	2025-08-14
2025-03-31	$3,611,827	131,963	-12.1%	Shares	Sole	2025-05-15
2024-12-31	$6,041,419	150,172	-61.7%	Shares	Sole	2025-02-14
2024-09-30	$18,565,807	392,263	—	Shares	Sole	2024-11-14
No filing history on record for this holder in this stock.